Immix Biopharma IMMX Income Statement (2020-2026)

NASDAQ IMMX
$13.97 +0.14 (+1.01%)
As of: Sep 4, 2026 · 3:08 PM EDT
Reported Financials

Immix Biopharma Quarterly Income Statement

Periods 23 quarters
Latest Jun 2026

Immix Biopharma reported net income of -$11.56M for the quarter ended Jun 2026. This income statement covers 23 quarters of results from Dec 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
3.38M3.67M13.86M13.91M13.93M13.89M13.95M16.26M19.61M19.92M26.40M27.43M27.48M27.54M27.85M28.41M33.04M32.97M53.01M71.54M
Operating items
Research & DevelopmentR&D
0.03M0.01M0.63M0.61M0.70M2.26M1.32M2.21M2.11M3.10M3.25M2.22M4.45M1.37M1.98M3.97M4.58M5.73M5.98M5.33M
Selling, General & AdministrativeSG&A
0.32M0.59M0.70M0.95M0.84M1.53M1.20M1.51M2.42M2.28M2.34M2.48M2.95M3.61M2.71M2.75M3.08M5.17M4.82M7.12M
Operating ExpensesOpex
0.35M0.60M1.33M1.56M1.53M3.79M2.52M3.72M4.52M5.38M5.59M4.70M7.39M4.99M4.68M6.72M7.66M10.89M10.80M12.46M
Operating IncomeOp. Inc
-0.35M-0.60M-1.33M-1.56M-1.53M-3.79M-2.52M-3.72M-4.52M-5.38M-5.59M-4.70M-7.39M-4.99M-4.68M-6.72M-7.66M-10.89M-10.80M-12.46M
EBIT
-0.35M-0.60M-1.33M-1.56M-1.53M-3.79M-2.52M-3.72M-4.52M-5.38M-5.59M-4.70M-7.39M-4.99M-4.68M-6.72M-7.66M-10.89M-10.80M-12.46M
Non-operating items
Non Operating Interest Expenses
0.05M0.04M388.00109.00
Interest & Investment IncomeInt & Inv Inc
0.03M0.13M0.19M0.23M0.27M0.31M0.26M0.19M0.15M0.10M0.08M0.22M0.72M0.91M
Other Non Operating IncomeOther Non Op Inc.
-22.02M
Non Operating IncomeNon Op. Inc.
-0.05M-22.16M-388.00-109.000.03M0.13M0.19M0.23M0.27M0.31M0.26M0.19M0.15M0.10M0.08M0.22M0.72M0.91M
Net income details
EBT
-0.40M-22.75M-1.33M-1.56M-1.53M-3.79M-2.49M-3.59M-4.34M-5.15M-5.32M-4.40M-7.14M-4.80M-4.53M-6.61M-7.58M-10.68M-10.09M-11.54M
Tax ProvisionsTaxes
0.00M-5.12M0.00M0.00M0.00M-1.74M0.01M0.01M0.01M-4.33M0.01M0.01M0.01M-6.07M0.01M0.01M0.01M-8.26M0.01M
Profit After TaxPAT
-0.41M-22.75M-1.33M-1.56M-1.58M-3.77M-2.50M-3.60M-4.34M-5.16M-5.33M-4.41M-7.15M-4.86M-4.54M-6.62M-7.60M-10.65M-10.09M-11.56M
Income from Non-Controlling InterestsInc. Minority
-0.02M-0.02M-0.06M-0.07M-0.07M-0.01M
Income from Continuing OperationsIncome (Continuing)
-0.40M-17.63M-1.33M-1.56M-1.54M-2.05M-2.50M-3.60M-4.34M-0.82M-5.33M-4.41M-7.15M1.27M-4.54M-6.62M-7.59M-2.41M-10.09M-11.56M
Consolidated Net IncomeConsol Net Inc.
-0.40M-17.63M-1.33M-1.56M-1.54M-2.05M-2.50M-3.60M-4.34M-0.82M-5.33M-4.41M-7.15M1.27M-4.54M-6.62M-7.59M-2.41M-10.09M-11.56M
Income towards Parent CompanyParent Net Inc
-0.40M-17.63M-1.33M-1.56M-1.54M-2.05M-2.50M-3.60M-4.34M-0.82M-5.33M-4.41M-7.15M1.27M-4.54M-6.62M-7.59M-2.41M-10.09M-11.56M
Net Income towards Common StockholdersNet Income
-0.40M-17.63M-1.33M-1.56M-1.54M-2.05M-2.50M-3.60M-4.34M-0.82M-5.33M-4.41M-7.15M1.27M-4.54M-6.62M-7.59M-2.41M-10.09M-11.56M
Additional items
EPS (Basic)
-0.12-4.80-0.10-0.11-0.11-0.15-0.18-0.24-0.23-0.05-0.23-0.15-0.240.04-0.15-0.22-0.24-0.07-0.18-0.18
EPS (Diluted)
-0.11-0.11-0.15-0.18-0.24-0.23-0.05-0.23-0.15-0.240.04-0.15-0.22-0.24-0.07-0.18-0.18
Shares Outstanding
3.38M3.67M13.83M13.88M13.92M13.89M13.90M15.04M18.58M17.34M23.44M28.79M29.42M28.29M29.70M29.98M31.93M32.97M55.37M63.77M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
13.88M13.92M13.89M13.90M15.04M18.58M17.34M23.44M28.79M29.42M28.29M29.70M29.98M31.93M32.97M55.37M63.77M
EBITDA
-0.35M-0.60M-1.33M-1.56M-1.53M-3.79M-2.52M-3.72M-4.52M-5.38M-5.59M-4.70M-7.39M-4.99M-4.68M-6.72M-7.66M-10.89M-10.80M-12.46M
Interest ExpensesInt Expense
0.05M0.04M388.00109.00
Tax Rate
-0.3322.52-0.12-0.11-0.1145.89-0.21-0.18-0.1684.07-0.17-0.23-0.16126.42-0.22-0.13-0.1077.40-0.12